Moderna's Spikevax vaccine has been fully approved for children with high-risk conditions, the first vaccine to do so.

A new scientific study has found that Pfizer’s COVID-19 vaccine may cause temporary changes in the eyes’ corneal structure, ...

In a July 9 memo, the director of the FDA's Center for Biologics Evaluation and Research contended there was not enough ...

Vinay Prasad overruled other reviewers for a third time in recent months in clearing only narrow use of Moderna's vaccine in ...

The company expects to make the updated Spikevax available to U.S. patients in time for the 2025-26 respiratory virus season.

Moderna, already in cash-saving mode amid uncertain vaccine dynamics, is backing off from its plans to construct an mRNA drug ...

Moderna (MRNA) stock in focus as the company cancels plans for an mRNA manufacturing plant in Japan amid a challenging ...

Cambridge: Moderna has received approval from the U.S. Food and Drug Administration (FDA) for the supplemental Biologics ...

The multicomponent mRNA-1083 vaccine elicited noninferior immune responses in adult patients when compared with coadministered influenza and COVID-19 vaccines.

Researchers are ushering in a new era of vaccine design that promises to be faster, more precise, and capable of tackling humanity’s most stubborn diseases.

When ticks bite us, they release thousands of proteins through their saliva. Could a vaccine for the right ones stop ticks ...

This stock used to be a highflyer but has struggled in recent years as demand waned for its flagship product. Though Moderna ...